Immunovant
IMVT
#3137
Rank
C$5.51 B
Marketcap
$37.58
Share price
0.75%
Change (1 day)
-31.65%
Change (1 year)

P/E ratio for Immunovant (IMVT)

P/E ratio as of December 2024 (TTM): -13.4

According to Immunovant's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.399. At the end of 2022 the company had a P/E ratio of -10.7.

P/E ratio history for Immunovant from 2019 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-10.763.15%
2021-6.55-81.13%
2020-34.7-62.15%
2019-91.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-3.77-71.89%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.